SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to show a fall in quarterly revenue when it reports results on February 11 for the period ending December 31 2024
The Cambridge Massachusetts-based company is expected to report a 81.5% decrease in revenue to $14.441 million from $77.97 million a year ago, according to the mean estimate from 17 analysts, based on LSEG data.
LSEG's mean analyst estimate for SAGE Therapeutics Inc is for a loss of $1.51 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 15 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.83, above its last closing price of $7.28.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.53 | -1.53 | -1.53 | Met | 0.2 |
Jun. 30 2024 | -1.70 | -1.66 | -1.70 | Missed | -2.5 |
Mar. 31 2024 | -1.64 | -1.65 | -1.80 | Missed | -9.3 |
Dec. 31 2023 | -1.65 | -1.28 | -1.80 | Missed | -40.9 |
Sep. 30 2023 | -2.76 | -2.73 | -3.37 | Missed | -23.4 |
Jun. 30 2023 | -2.56 | -2.55 | -2.68 | Missed | -4.9 |
Mar. 31 2023 | -2.47 | -2.50 | -2.46 | Beat | 1.4 |
Dec. 31 2022 | -2.41 | -2.39 | -2.47 | Missed | -3.5 |
This summary was machine generated February 7 at 21:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。